Tobramycin Sulfate Powder Spray Drying Process
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing methods for preparing tobramycin sulfate powder, such as lyophilization, are inefficient and energy-intensive, and previous attempts at spray drying using isopropanol result in powders unsuitable for intravenous use due to residual solvent toxicity and low production rates.
Innovation Solution
A method involving the aseptic spray drying of a tobramycin sulfate solution, formed by dissolving tobramycin in water and mixing with sulfuric acid, followed by filtration and spray drying with controlled temperature and gas composition, to produce a powder suitable for Tobramycin for Injection, which can be reconstituted for intravenous administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lyophilization is used to prepare tobramycin sulfate powder, then the powder quality is maintained, but the process requires high energy consumption and long cycle time
Solution Approach 1:
The patent changes the fundamental drying parameters by replacing lyophilization with spray drying technology. This involves changing the phase transition method from freeze-drying to atomization-drying, adjusting the solution concentration to 5-20% tobramycin sulfate in water, and controlling the spray drying temperature to achieve rapid water evaporation while maintaining powder quality and reducing energy consumption by over 50%
Solution Approach 2:
The patent replaces the mechanical freeze-drying system with a spray drying system that uses atomization technology. The solution is atomized into fine droplets through a spray nozzle and rapidly dried by hot air or inert gas flow, substituting the complex freeze-drying mechanical process with a simpler thermal drying process that achieves the same quality outcome with lower energy input
2Productivity
If spray drying is used to prepare tobramycin sulfate powder, then energy consumption is reduced and production efficiency is increased, but the process must ensure absence of toxic solvent residues
Solution Approach 1:
The patent employs an inert atmosphere approach by using purified water as the solvent instead of organic solvents like isopropanol. The spray drying process is conducted in a controlled environment with inert gas (nitrogen or filtered air) to prevent contamination and ensure the absence of toxic residues in the final powder product, making it suitable for intravenous injection
Solution Approach 2:
The patent uses purified water as a disposable, non-toxic solvent that evaporates completely during spray drying without leaving harmful residues. This replaces the need for extensive solvent removal and purification steps required when using organic solvents, simplifying the process while ensuring product safety for intravenous administration
3Ease of manufacture
If isopropanol is used as solvent in spray drying, then spray drying can be performed, but the resulting powder contains toxic residues and is not suitable for intravenous use
Solution Approach 1:
The patent fundamentally changes the solvent parameter from isopropanol to purified water. This parameter change maintains the feasibility of spray drying while eliminating the toxicity issue. The water-based solution is atomized and dried to produce tobramycin sulfate powder suitable for intravenous injection, completely avoiding isopropanol residue concerns
4Ease of operation
If low concentration tobramycin suspension is used for spray drying, then spray drying can be performed, but the production rate is quite low
Solution Approach 1:
The patent optimizes the solution concentration parameter to 5-20% tobramycin sulfate in water, which is higher than the 5% (w/v) used in previous isopropanol-based suspensions. This concentration optimization maintains good spray drying operability while significantly increasing the amount of active ingredient processed per unit time, thereby improving production rate and making the process economically viable
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method reduces energy consumption, increases production efficiency, and produces a tobramycin sulfate powder with an amorphous structure, suitable for intravenous use, meeting USP specifications with controlled pH and impurity levels, and improved safety and environmental friendliness.
Implementation Method 1
the liquid droplets contact with the heated gas, e.g., air or N2, and then the liquid droplets evaporate to accompany with the nucleation of particles in a short period about a few seconds
Implementation Method 2
The first one is the atomization of the concentrated solution into numerous liquid droplets
Implementation Method 3
the dried particles are collected by a cyclone system incorporated with a bag filter or wet scrubber
Data Source
AI summary
A method for preparing tobramycin sulfate powder for injection is provided. The method includes steps of providing a sterile tobramycin sulfate solution; and aseptically spray drying the tobramycin sulfate solution to obtain the tobramycin sulfate powder.